149 related articles for article (PubMed ID: 30682720)
1. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Liu Y; Jiang X; Gu Y; Chen Y
Int Immunopharmacol; 2019 Apr; 69():79-87. PubMed ID: 30682720
[TBL] [Abstract][Full Text] [Related]
2. Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor.
Liu Y; Xing H; Jiang X; Chen Y; Huang M; Yu S
Biomed Pharmacother; 2020 Mar; 123():109755. PubMed ID: 31926375
[TBL] [Abstract][Full Text] [Related]
3. Diallyl Trisulfide Inhibits Growth of NCI-H460
Jiang X; Zhu X; Liu N; Xu H; Zhao Z; Li S; Li S; Cai J; Cao J
Int J Biol Sci; 2017; 13(2):167-178. PubMed ID: 28255269
[TBL] [Abstract][Full Text] [Related]
4. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
[TBL] [Abstract][Full Text] [Related]
5. Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer.
Zhu H; Zhu Z; Huang W; Cheng X; He J; Xiong C; Han J
Cutan Ocul Toxicol; 2018 Mar; 37(1):96-99. PubMed ID: 28707485
[TBL] [Abstract][Full Text] [Related]
6. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
7. Diallyl trisulfide protects against concanavalin A-induced acute liver injury in mice by inhibiting inflammation, oxidative stress and apoptosis.
Ding Y; Yu Z; Zhang C
Life Sci; 2021 Aug; 278():119631. PubMed ID: 34022202
[TBL] [Abstract][Full Text] [Related]
8. Garlic-derived organosulfur compound exerts antitumor efficacy via activation of MAPK pathway and modulation of cytokines in SGC-7901 tumor-bearing mice.
Jiang X; Zhu X; Huang W; Xu H; Zhao Z; Li S; Li S; Cai J; Cao J
Int Immunopharmacol; 2017 Jul; 48():135-145. PubMed ID: 28501767
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
10. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.
Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV
Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905
[TBL] [Abstract][Full Text] [Related]
11. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW; Pang JS; Ko YS; Chang CJ; Wang CW; Chen WT; Chen CB; Hui RC; Hung SI; Lu LY; Lu KL; Wang CL; Wu CE; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Chen MJ; Chung WH
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):328-339. PubMed ID: 36366861
[TBL] [Abstract][Full Text] [Related]
12. Diallyl trisulfide inhibits phorbol ester-induced tumor promotion, activation of AP-1, and expression of COX-2 in mouse skin by blocking JNK and Akt signaling.
Shrotriya S; Kundu JK; Na HK; Surh YJ
Cancer Res; 2010 Mar; 70(5):1932-40. PubMed ID: 20179211
[TBL] [Abstract][Full Text] [Related]
13. The cardioprotective effects of diallyl trisulfide on diabetic rats with ex vivo induced ischemia/reperfusion injury.
Jeremic JN; Jakovljevic VL; Zivkovic VI; Srejovic IM; Bradic JV; Bolevich S; Nikolic Turnic TR; Mitrovic SL; Jovicic NU; Tyagi SC; Jeremic NS
Mol Cell Biochem; 2019 Oct; 460(1-2):151-164. PubMed ID: 31280436
[TBL] [Abstract][Full Text] [Related]
14. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
15. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression.
Ikarashi N; Kaneko M; Watanabe T; Kon R; Yoshino M; Yokoyama T; Tanaka R; Takayama N; Sakai H; Kamei J
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260143
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of diallyl trisulfide in SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis.
Guo Y; Zhang K; Wang Q; Li Z; Yin Y; Xu Q; Duan W; Li C
Brain Res; 2011 Feb; 1374():110-5. PubMed ID: 21147075
[TBL] [Abstract][Full Text] [Related]
17. Diallyl trisulfide induces apoptosis in human breast cancer cells through ROS-mediated activation of JNK and AP-1.
Na HK; Kim EH; Choi MA; Park JM; Kim DH; Surh YJ
Biochem Pharmacol; 2012 Nov; 84(10):1241-50. PubMed ID: 22981381
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Kau HC; Tsai CC
Cutan Ocul Toxicol; 2016 Sep; 35(3):257-9. PubMed ID: 26340340
[TBL] [Abstract][Full Text] [Related]
19. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo.
Lai KC; Kuo CL; Ho HC; Yang JS; Ma CY; Lu HF; Huang HY; Chueh FS; Yu CC; Chung JG
Phytomedicine; 2012 May; 19(7):625-30. PubMed ID: 22397993
[TBL] [Abstract][Full Text] [Related]
20. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice.
Singh SV; Powolny AA; Stan SD; Xiao D; Arlotti JA; Warin R; Hahm ER; Marynowski SW; Bommareddy A; Potter DM; Dhir R
Cancer Res; 2008 Nov; 68(22):9503-11. PubMed ID: 19010926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
